The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Surely this is still cheap even if the deal fails ?
The Board believes that industry recognition of the Company's growth prospects explains the significant attention the Company is receiving from a number of international companies, many of which are interested in some form of, co-operation, including: (co)-promotion; licensing of products; repatriation of distribution agreements; development collaborations; and merger and acquisition opportunities.
As a result of the deliberation process arising out of these opportunities, the Board recognises that there may be organisations better placed to build on the successes to date.
Â
Accordingly, the Board has decided to appoint Rothschild to assist it in evaluating the optimum way to realise the considerable value in the Company which may, or may not, include the sale of all or part of the Company. The Board believes that Sinclair has a secure future as an independent business and will only engage with those willing to recognise and support the Company's significant growth potential.
Â
The UK Takeover Panel ("the Panel") has agreed that any such discussions with third parties may be conducted within the framework set out in Note 2 on Rule 2.6 of the Takeover Code (the "Code"). The Panel has granted a dispensation from the requirements of Rules 2.4(a), 2.4(b) and 2.6(a) of the Code such that any interested party will not be required to be publicly identified as a result of this announcement (subject to note 3 to Rule 2.2 of the Code) and will not be subject to the 28 day deadline referred to in Rule 2.6(a), for so long as it is participating in discussions with Sinclair.
Â
How this possible offer came in on same day as trading update. Company is on a very sound financial footing, no need to sell unless a very good offer. BoD will outright reject anything under 50p one would think already!
LONDON (Alliance News) - Sinclair Pharma PLC on Thursday confirmed that it is in talks with China Grand Enterprises Inc regarding a possible offer for the company.
The pharmaceutical company, noting the recent share price movement, said that it was approached by China Grand and its affiliate Huadong Medicine Co Ltd. It, however, added that there can be no certainty that an offer will be made.
The stock was trading 25% higher on Thursday at 22.85 pence per share.
Beijing-based China Grand Enterprises is an investment company focused on pharmaceuticals and healthcare, commodities trading, real estate investment, financial service and other sectors.
Expecting strong growth..trading update ‘..Unaudited sales for the six months ended 30 June 2018 were £21.3 million, (£21.6 million at constant currency) compared with sales of £20.1 million for the same period in 2017, representing headline growth of 6.0%. Performance of the Group's ex-US business has been encouraging with sales of £20.5 million in the first six months (2017: £17.6 million) representing actual growth of 16.5% and 18.0% on a constant currency basis.’
If a bidding war erupts then who knows!
So... We could be looking at 100% from here, minimum ????
Minimum, board have no reason to sell so must be high enough for them to be interested
When he was dreaming...
Possibly as high as 35p unless there is a bidding war then the sky is the limit
Announcing the possible takeover bid too, hopefully this gets some traction from here
Where did you see £1.32. ????
mid thirties i will be happy with .
So if i'm right, China Grand Pharmaceutical have a MCAP of ~1.2bn and looking to buy out Sinclair Pharma
£1.32 apparently!
Is this worth a punt? What we the offer be?
The offer price ?? Any ideas ????
Booom
Rumours are true... In talks !!
23p breached!
Let’s see if these rumours are true
China Grand is said in talks to acquire Sinclair
Looks like 4/5 weeks of churning, before we proceed further!
Definitely on upward trend. Onwards to 25p and beyond
Ok I now see 36m was used in marketing costs as well, making a net loss of 3m. Hence the SP. So they're projecting growth of 15% , as they are promoting and expanding their customer base. So in the future profits should exceed 50m+, and market cap to 500m. Currently 90m. Therefore x5 bagger in a couple of years?